We are live on ! Find out more
DB

DCVC Bio Portfolio holdings

AUM $313K
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$313K
AUM Growth
-$70.9M
Cap. Flow
-$61.6M
Cap. Flow %
-19,683.11%
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$61.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCL icon
1
AbCellera Biologics
ABCL
$1.8B
$313K 100%
29,411
-7,276,350
-100% -$61.6M

Similar funds

FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
SP
Sage Partners Hong Kong $23K AUM
MGPI
Maveron General Partner IV Seattle, Washington $8K AUM
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return

DCVC Bio's Q2 2022 Portfolio in Review

As of Q2 2022, DCVC Bio held 1 position worth $313K, down 100% from $71.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

DCVC Bio withdrew a net $61.6M in Q2 2022, reducing 1 holding. Its largest reduction was AbCellera Biologics, cutting an estimated $61.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • DCVC Bio's biggest Q2 2022 reduction was AbCellera Biologics, cutting an estimated $61.6M.
  • DCVC Bio's ten largest holdings make up 100% of its $313K portfolio in Q2 2022.
  • DCVC Bio opened 0 new positions and closed 0 in Q2 2022.
  • DCVC Bio's portfolio value fell 100% quarter-over-quarter to $313K.

Based on DCVC Bio's 13F filing for Q2 2022, filed 14 Nov 2022.